Literature DB >> 22975850

Striatal neuronal loss correlates with clinical motor impairment in Huntington's disease.

Zhihong Guo1, Gay Rudow, Olga Pletnikova, Kari-Elise Codispoti, Brent A Orr, Barbara J Crain, Wenzhen Duan, Russell L Margolis, Adam Rosenblatt, Christopher A Ross, Juan C Troncoso.   

Abstract

Huntington's disease (HD) is characterized clinically by chorea, motor impairment, psychiatric manifestations, and dementia. Atrophy of the striatum is the neuropathological hallmark of HD, and previous studies have suggested that striatal atrophy correlates more closely with motor impairment than with chorea. Motor impairment, as measured by motor impairment score, correlates with functional disability in HD patients, but chorea does not. In this study, we investigated the relation between neuronal loss and these motor features. We conducted neuropathological and stereologic assessments of neurons in putamen and subthalamic nuclei in HD patients and age-matched controls. In putamen, we estimated the total number and volume of medium spiny neurons labeled with dopamine- and cAMP-regulated phosphoprotein 32 kDa (DARPP-32). In subthalamic nuclei, we estimated the total number of neurons on hematoxylin & eosin/luxol fast blue stains. In putamen of HD, immunohistochemistry showed DARPP-32 neuronal atrophy with extensive disruption of neurites and neuropil; stereologic studies found significant decreases in both the number and size of DARPP-32 neurons; we also detected a significant reduction of overall putamen volume in HD patients, compared to controls. In subthalamic nuclei, there was a mild, but significant, neuronal loss in the HD group. The loss of neurons in putamen and subthalamic nuclei as well as putaminal atrophy were significantly correlated with severity of motor impairment, but not with chorea. Our findings suggest that neuronal loss and atrophy in striatum and neuronal loss in subthalamic nuclei contribute specifically to the motor impairment of HD, but not to chorea.
Copyright © 2012 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22975850      PMCID: PMC3455126          DOI: 10.1002/mds.25159

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  40 in total

1.  The subthalamic nucleus: myth and opportunities.

Authors:  A M Lozano
Journal:  Mov Disord       Date:  2001-03       Impact factor: 10.338

Review 2.  The subthalamic nucleus in the context of movement disorders.

Authors:  Clement Hamani; Jean A Saint-Cyr; Justin Fraser; Michael Kaplitt; Andres M Lozano
Journal:  Brain       Date:  2003-11-07       Impact factor: 13.501

Review 3.  Brain networks in Huntington disease.

Authors:  David Eidelberg; D James Surmeier
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

Review 4.  Development of biomarkers for Huntington's disease.

Authors:  David W Weir; Aaron Sturrock; Blair R Leavitt
Journal:  Lancet Neurol       Date:  2011-06       Impact factor: 44.182

Review 5.  Huntington's disease: from molecular pathogenesis to clinical treatment.

Authors:  Christopher A Ross; Sarah J Tabrizi
Journal:  Lancet Neurol       Date:  2011-01       Impact factor: 44.182

6.  Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis.

Authors:  Sarah J Tabrizi; Rachael I Scahill; Alexandra Durr; Raymund Ac Roos; Blair R Leavitt; Rebecca Jones; G Bernhard Landwehrmeyer; Nick C Fox; Hans Johnson; Stephen L Hicks; Christopher Kennard; David Craufurd; Chris Frost; Douglas R Langbehn; Ralf Reilmann; Julie C Stout
Journal:  Lancet Neurol       Date:  2010-12-02       Impact factor: 44.182

7.  Onset and progression of pathologic atrophy in Huntington disease: a longitudinal MR imaging study.

Authors:  N Z Hobbs; J Barnes; C Frost; S M D Henley; E J Wild; K Macdonald; R A Barker; R I Scahill; N C Fox; S J Tabrizi
Journal:  AJNR Am J Neuroradiol       Date:  2010-02-11       Impact factor: 3.825

8.  Localization of substance P-like immunoreactivity in neurons and nerve terminals in the neostriatum of the rat: a correlated light and electron microscopic study.

Authors:  J P Bolam; P Somogyi; H Takagi; I Fodor; A D Smith
Journal:  J Neurocytol       Date:  1983-04

9.  Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease.

Authors:  R J Ferrante; M F Beal; N W Kowall; E P Richardson; J B Martin
Journal:  Brain Res       Date:  1987-05-12       Impact factor: 3.252

Review 10.  MRI biomarkers in Huntington's disease.

Authors:  Simon van den Bogaard; Eve Dumas; Jeroen van der Grond; Mark van Buchem; Raymund Roos
Journal:  Front Biosci (Elite Ed)       Date:  2012-01-01
View more
  28 in total

Review 1.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update. II. Hyperkinetic disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-24       Impact factor: 3.575

Review 2.  Young-onset dementia.

Authors:  Dulanji K Kuruppu; Brandy R Matthews
Journal:  Semin Neurol       Date:  2013-11-14       Impact factor: 3.420

Review 3.  Therapeutic approaches to Huntington disease: from the bench to the clinic.

Authors:  Nicholas S Caron; E Ray Dorsey; Michael R Hayden
Journal:  Nat Rev Drug Discov       Date:  2018-09-21       Impact factor: 84.694

Review 4.  Huntington disease: natural history, biomarkers and prospects for therapeutics.

Authors:  Christopher A Ross; Elizabeth H Aylward; Edward J Wild; Douglas R Langbehn; Jeffrey D Long; John H Warner; Rachael I Scahill; Blair R Leavitt; Julie C Stout; Jane S Paulsen; Ralf Reilmann; Paul G Unschuld; Alice Wexler; Russell L Margolis; Sarah J Tabrizi
Journal:  Nat Rev Neurol       Date:  2014-03-11       Impact factor: 42.937

5.  Perceptions of the impact of chorea on health-related quality of life in Huntington disease (HD): A qualitative analysis of individuals across the HD spectrum, family members, and clinicians.

Authors:  Carey Wexler Sherman; Ravi Iyer; Victor Abler; Alexandria Antonelli; Noelle E Carlozzi
Journal:  Neuropsychol Rehabil       Date:  2019-03-08       Impact factor: 2.868

6.  Mapping the order and pattern of brain structural MRI changes using change-point analysis in premanifest Huntington's disease.

Authors:  Dan Wu; Andreia V Faria; Laurent Younes; Susumu Mori; Timothy Brown; Hans Johnson; Jane S Paulsen; Christopher A Ross; Michael I Miller
Journal:  Hum Brain Mapp       Date:  2017-06-28       Impact factor: 5.038

7.  SorCS2-mediated NR2A trafficking regulates motor deficits in Huntington's disease.

Authors:  Qian Ma; Jianmin Yang; Teresa A Milner; Jean-Paul G Vonsattel; Mary Ellen Palko; Lino Tessarollo; Barbara L Hempstead
Journal:  JCI Insight       Date:  2017-05-04

Review 8.  Determinants of functional disability in Huntington's disease: role of cognitive and motor dysfunction.

Authors:  Christopher A Ross; Alex Pantelyat; Jane Kogan; Jason Brandt
Journal:  Mov Disord       Date:  2014-09-15       Impact factor: 10.338

Review 9.  Magnetic resonance imaging striatal volumes: a biomarker for clinical trials in Huntington's disease.

Authors:  Elizabeth H Aylward
Journal:  Mov Disord       Date:  2014-08-27       Impact factor: 10.338

10.  Reduced striato-cortical and inhibitory transcallosal connectivity in the motor circuit of Huntington's disease patients.

Authors:  Clara Garcia-Gorro; Ruth de Diego-Balaguer; Saul Martínez-Horta; Jesus Pérez-Pérez; Jaime Kulisevsky; Nadia Rodríguez-Dechicha; Irene Vaquer; Susana Subira; Matilde Calopa; Esteban Muñoz; Pilar Santacruz; Jesús Ruiz-Idiago; Celia Mareca; Nuria Caballol; Estela Camara
Journal:  Hum Brain Mapp       Date:  2017-10-08       Impact factor: 5.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.